Brokerages Set Evolus, Inc. (NASDAQ:EOLS) PT at $16.00

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $16.00.

Several analysts have recently issued reports on the company. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday, March 4th. Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday.

Insider Activity

In other news, insider David Moatazedi sold 13,669 shares of the company’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the sale, the insider directly owned 604,700 shares in the company, valued at $2,872,325. This represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.00% of the stock is owned by corporate insiders.

Institutional Trading of Evolus

Several institutional investors and hedge funds have recently made changes to their positions in EOLS. Larson Financial Group LLC lifted its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares during the period. Meeder Asset Management Inc. purchased a new position in Evolus during the fourth quarter worth about $34,000. Wexford Capital LP purchased a new position in Evolus during the third quarter worth about $37,000. Aquatic Capital Management LLC purchased a new position in Evolus during the third quarter worth about $48,000. Finally, State of Wyoming purchased a new position in Evolus during the fourth quarter worth about $63,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Stock Performance

Evolus stock opened at $6.63 on Wednesday. The firm has a market capitalization of $436.62 million, a price-to-earnings ratio of -9.90 and a beta of 1.34. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $10.20. The stock’s fifty day moving average is $5.82 and its two-hundred day moving average is $5.55.

Evolus (NASDAQ:EOLS) last posted its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $73.14 million during the quarter, compared to the consensus estimate of $72.52 million. During the same quarter last year, the business earned ($0.30) earnings per share. As a group, sell-side analysts forecast that Evolus will post -0.38 EPS for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.